ATE108186T1 - Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen. - Google Patents

Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen.

Info

Publication number
ATE108186T1
ATE108186T1 AT85103559T AT85103559T ATE108186T1 AT E108186 T1 ATE108186 T1 AT E108186T1 AT 85103559 T AT85103559 T AT 85103559T AT 85103559 T AT85103559 T AT 85103559T AT E108186 T1 ATE108186 T1 AT E108186T1
Authority
AT
Austria
Prior art keywords
synthetic
cysteine
oxidizing agent
microbially
manufactured
Prior art date
Application number
AT85103559T
Other languages
German (de)
English (en)
Inventor
Ze Ev Shaked
Sidney Norman Wolfe
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27081941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE108186(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Application granted granted Critical
Publication of ATE108186T1 publication Critical patent/ATE108186T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT85103559T 1984-03-28 1985-03-26 Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen. ATE108186T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59435184A 1984-03-28 1984-03-28
US06/661,902 US4530787A (en) 1984-03-28 1984-10-17 Controlled oxidation of microbially produced cysteine-containing proteins

Publications (1)

Publication Number Publication Date
ATE108186T1 true ATE108186T1 (de) 1994-07-15

Family

ID=27081941

Family Applications (2)

Application Number Title Priority Date Filing Date
AT85103559T ATE108186T1 (de) 1984-03-28 1985-03-26 Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen.
AT93203286T ATE196769T1 (de) 1984-03-28 1985-03-26 Kontrollierte oxidation von mikrobiell herstellten, cystein-enthaltenden proteinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT93203286T ATE196769T1 (de) 1984-03-28 1985-03-26 Kontrollierte oxidation von mikrobiell herstellten, cystein-enthaltenden proteinen

Country Status (5)

Country Link
US (1) US4530787A (enExample)
EP (2) EP0606673B1 (enExample)
AT (2) ATE108186T1 (enExample)
CA (1) CA1233172A (enExample)
DE (3) DE3587873T2 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
JPS60115528A (ja) * 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4761375A (en) * 1984-05-08 1988-08-02 Genetics Institute, Inc. Human interleukin-2 cDNA sequence
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US5248769A (en) * 1985-06-26 1993-09-28 Cetus Oncology Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
CA1291706C (en) * 1986-04-03 1991-11-05 Alfred Rudolph COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2
DE3611817A1 (de) * 1986-04-08 1987-10-15 Boehringer Mannheim Gmbh Verfahren zur renaturierung von proteinen
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4777242A (en) * 1986-10-10 1988-10-11 Phillips Petroleum Company Purification of recombinant tumor necrosis factor
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
CA1339757C (en) 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
WO1988008428A1 (en) * 1987-04-28 1988-11-03 Amgen Inc. Method for purifying granulocyte/macrophage colony stimulating factor
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
AU622860B2 (en) * 1987-05-11 1992-04-30 Novartis Vaccines And Diagnostics, Inc. Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US4801691A (en) * 1987-05-15 1989-01-31 International Minerals & Chemical Corp. Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions
US4985544A (en) * 1987-08-04 1991-01-15 Kyowa Hakko Kogyo Co., Ltd. Process for renaturing fish growth hormone
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5759815A (en) * 1988-02-11 1998-06-02 Creative Biomolecules, Inc. Production of platelet derived growth factor (PDGF) an muteins thereof
CA1340586C (en) * 1988-09-23 1999-06-08 Cetus Corporation Process for recovering microbially produced interferon-beta
JP2682061B2 (ja) * 1988-10-07 1997-11-26 藤沢薬品工業株式会社 ペプチドの分子内ジスルフィド結合の形成法
US5204256A (en) * 1989-09-06 1993-04-20 Behringwerke Aktiengesellschaft Process for the purification of plasminogen activator inhibitor 2 (pai-2)
US5023323A (en) * 1990-09-12 1991-06-11 Monsanto Company Method of somatotropin naturation
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
JP3021040B2 (ja) * 1990-11-23 2000-03-15 ヘキスト・マリオン・ルセル 少なくとも１個の分子内ジスルフィド結合を含有する蛋白質を相当する還元された組替え蛋白質を５．０以下のｐＨで酸化することによって製造する方法
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) * 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
AU687763B2 (en) * 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
AR033622A1 (es) 2001-03-29 2003-12-26 Schering Corp Compuestos aril oxima-piperazinas, composicion farmaceutica, el uso de dichos compuestos para la manufactura de medicamentos utiles como antagonistas de ccr5 y un equipo
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
HUP0500472A2 (hu) * 2001-10-15 2005-08-29 Chiron Corporation Szepszis kezelése kis dózisú szöveti faktor bioszintézis inhibitor (TFPI) beadásával
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
RU2006104023A (ru) * 2003-07-11 2006-07-27 Шеринг Акциенгезельшафт (De) УЛУЧШЕННЫЕ РЕКОМБИНАНТНЫЕ ПОЛИПЕПТИДЫ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА -БЕТА-1b
DK2149585T3 (da) 2003-11-04 2013-10-21 Novartis Vaccines & Diagnostic Anvendelse af antagonistiske anti-CD40-monoklonale antistoffer
CA2560103A1 (en) * 2004-03-17 2005-11-24 Chiron Corporation Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
ES2318916B1 (es) * 2005-02-07 2010-03-22 Chiron Corporation Procedimiento para preparar aldesleukina para uso farmaceutico.
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
ATE503744T1 (de) 2006-08-16 2011-04-15 Hoffmann La Roche Nicht-nukleosidische reverse-transkriptase-hemmer
MX2009005881A (es) 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
WO2008145562A1 (en) 2007-05-30 2008-12-04 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
WO2009045553A1 (en) * 2007-10-05 2009-04-09 Barofold, Inc. High pressure treatment of aggregated interferons
CA2709348C (en) 2007-12-21 2016-07-19 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors for treating human immunodeficiency virus (hiv-1) mediated diseases
AU2011229491B2 (en) 2010-03-17 2015-02-05 Ratiopharm Gmbh Method for obtaining biologically active recombinant human G-CSF
EP2655409A4 (en) 2010-12-22 2015-07-01 Univ Leland Stanford Junior SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
PL2683395T3 (pl) 2011-03-11 2019-04-30 Assist Publique Hopitaux De Paris Zastosowanie małych dawek il-2 do leczenia cukrzycy typu 1
EP2768844B1 (en) * 2011-10-21 2016-04-27 Tanvex Biologics Corp. Separation of acetylated proteins from unacetylated proteins
US10183061B2 (en) 2013-06-25 2019-01-22 Icm (Institut Du Cerveau Et De La Moelle Epiniere) Boosting Treg cells for treating Alzheimer disease and related disorders
WO2015042707A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-2 fusion proteins and uses thereof
EP2918285A1 (en) 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 for treating food allergy
CN106659757B (zh) 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 白介素2的超级激动剂、部分激动剂和拮抗剂
US10457716B2 (en) 2014-08-06 2019-10-29 University Of Notre Dame Du Lac Protein folding and methods of using same
JP6941561B2 (ja) 2014-10-09 2021-09-29 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン
CN108135841B (zh) 2015-10-22 2024-03-05 艾尔图制药公司 Il-2的药物组合物
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
SG11202004581PA (en) 2017-11-21 2020-06-29 Univ Leland Stanford Junior Partial agonists of interleukin-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
JP7770923B2 (ja) 2019-04-16 2025-11-17 バッヘン・ホールディング・アクチエンゲゼルシャフト ジスルフィド結合ペプチドの製造
CN114679909A (zh) 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM靶向的免疫耐受
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
EP4647123A2 (en) 2020-03-06 2025-11-12 Centre Hospitalier Universitaire de Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
WO2024121173A1 (en) 2022-12-05 2024-06-13 Centre Hospitalier Universitaire De Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061538A (en) * 1973-04-04 1977-12-06 Sandoz Ltd. Enzymatically oxidizing interferon
CH648331A5 (de) * 1979-07-31 1985-03-15 Hoffmann La Roche Homogenes fibroblasten-interferon und dessen herstellung.
US4414147A (en) * 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4405601A (en) * 1981-05-21 1983-09-20 Cancer Research Center Extraction and purification of biologically active lymphokines
US4478744A (en) * 1982-01-25 1984-10-23 Sherwood Medical Company Method of obtaining antibodies
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
EP0091539B2 (en) * 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
EP0092163B1 (en) * 1982-04-20 1988-09-28 Sloan-Kettering Institute For Cancer Research Purification of interleukin 2
JPS58201794A (ja) * 1982-05-17 1983-11-24 Toray Ind Inc ヒトインターフェロンβの濃縮精製法
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
GR79124B (enExample) * 1982-12-22 1984-10-02 Genentech Inc
DE122080T1 (de) * 1983-03-25 1985-05-23 Celltech Ltd., Slough, Berkshire Verfahren zur herstellung eines proteins.
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions

Also Published As

Publication number Publication date
DE156354T1 (de) 1986-03-20
EP0606673A3 (en) 1995-01-25
DE3588226D1 (de) 2000-11-09
US4530787B1 (enExample) 1993-07-20
EP0156354A3 (en) 1987-10-28
EP0606673B1 (en) 2000-10-04
DE3587873D1 (de) 1994-08-11
EP0156354B1 (en) 1994-07-06
ATE196769T1 (de) 2000-10-15
EP0606673A2 (en) 1994-07-20
EP0156354A2 (en) 1985-10-02
DE3587873T2 (de) 1994-10-20
CA1233172A (en) 1988-02-23
US4530787A (en) 1985-07-23

Similar Documents

Publication Publication Date Title
US4530787B1 (enExample)
ES549135A0 (es) Un metodo para oxidar una proteina recombinante totalmente reducida
ATE156355T1 (de) Stabile zusammensetzungen von askorbinsäure
ES8603271A1 (es) Un metodo de producir una composicion de interleuquina-2
AU1141288A (en) Production of proteins in active forms
BE904831A (fr) Composition d'activateur tissulaire du plasminogene.
ES552233A0 (es) Un metodo para la solubilizacion y renaturalizacion de proteina somatotropina
DE69029540D1 (de) Oxidative Denaturierung von Eiweissanalyten
ATE82857T1 (de) Interleukin-2-zusammensetzungen.
DE3575144D1 (de) Platinkomplexe von aliphatischen tricarbonsaeuren.
CA1263590C (en) CYANIDE-FREE REAGENT FOR THE DETERMINATION OF HEMOGLOBIN
ES557404A0 (es) Procedimiento de dosificacion de anticuerpos dirigidos contra toxinas bacterianas.
DK44185D0 (da) Stabiliseret enzymkonjugat
AU564269B2 (en) Compositions containing s-adenosyl-l methionine
FI872869A0 (fi) Foerfarande foer stabilisering av enzymet laktoperoxidas i produkter.
JPS56128792A (en) Novel biochemically active substance, its manufacture and medicinal composition containing it
SU1212247A1 (ru) Твердый электролит для химического источника тока
ATE31623T1 (de) Injizierbare zusammensetzungen von bbm-928a.
KR950018051A (ko) 싸이모신-알파와 다른 싸이토킨이 융합된 융합 단백질

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time